The US President Donald Trump’s threat of 200% tariff in the drug industry is “shock” to be reflected in global supply chains.
Speaking at the White House on July 8, “We will soon declare anything in the pharmacy. It will be tariffed for people for about a year, a year and a half, and then be brought to the country as high as 200%.”
This continues to offer this, both countries and US trading secretary Howard Lutnick, which is in March 2025, this, this, this continued to ensure the forecast of both Trump and US Trading Secretary Howard Lutnick.
Cyrus fan, GLOBALLATA Group of Life Sciences, Scientific Analyst, Industrial Tariffs can be counterpropped for the US health system, not months, which moves rapidly until ten years old, he said.
Fan said: “Trump has repeatedly recommended the building of new production sites for drugs. In May, Trump has signed an executive order to help Pharma stream Set up new US production areas.
“Moving Pharma Production, the compromise has been offering Trump at the last cabinet meeting, this last cabinet continues to death in billions of dollars to increase the production existence.
Marko forgiveness of regular exports and international trade. The ability to expend and delay on both sides of the Atlantic. “
“Pharmaceutical supply chains are incredibly complicated, and any tariffs have real global results. Brown firms may have a coordinated diplomacy and sector to prevent production of the necessary goods in one night.”
Although the announcement on July 8, most of the pharmacies remained stable with a slightly less drip in large companies with global production capabilities. Eli Lilly’s shares were declared from $ 773.02 to $ 773.02 before $ 7,91.64. The shares of the Pharma giant are closing from $ 777.66.
Ireland admits 12 of the largest global manufacturers producing drugs or active ingredients for the American market.
Ireland’s medical and pharmaceutical exports in the United States earlier this year, according to April 15, in February 2025 there has been more than a year in a year Reuters.
In February, the Central Statistics Office of Ireland, this product reached 1.9 billion euros (11.8 million 11.8 billion) in the same month of this product exported to the United States.
In addition to Ireland, India and China are also the main suppliers of a large operating organization (CMO), such as large plants in China, which are large crops in China, and large plants in China.
Several pharmaceutical companies have already made announcements for investment for testing and polishing the impact of incoming pharma tariffs Manufacturing tools in the United States. Eli Lilly will invest $ 27 billion To the US-based sites Novartis, Sanofiand others made similar actions to get rid of land in the country.
Manage the changing tariff view with real-time data and market leading analysis.
Request a free demo for Globallata’s strategic intelligence here.
“Trump’s 200% tariff threat can send shockwaves via Pharma Supply Chains” first created and published Clinical Test ArenaA global brand.
The information on this site has only been included in the faith for general information purposes. We are not intended to give advice for you to be careful and provide no representation or intended representation or intended representation or intended. You must receive professional or specialist recommendations before any action on the basis of our site.
